PharmExec

NOVEMBER 3, 2023

Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.

Patients 52

Patients 52

Pharmaceutical Technology

JUNE 5, 2023

PharmaEssentia founder and CEO Ko-Chung Lin stated: “Expanding our geographic reach is critical to our mission to address clear gaps in therapeutic options for people with myeloproliferative neoplasms (MPNs). PharmaEssentia may be entitled to receive certain milestone payments along with royalties based on sales of the product.

Pharma 52

Pharma Marketing Specialization Medicine 52

Pharma Leaders

APRIL 4, 2023

During the extensive preclinical studies, superior transduction efficiency was seen of the RPE layer and the recovery of the retinal functions under HG004 when compared with AAV2-mediated gene replacement therapy via the company’s independently developed Rpe65 gene knockout (KO) murine disease model leveraging the clustered regularly interspaced palindromic (..)

Food and Drug Administration 52

Food and Drug Administration FDA Food Patients 52

Pharmaceutical Technology

FEBRUARY 15, 2023

KO-plus-transgenic humanisation involves generating genetically engineered (HumAb) mice by disrupting the endogenous mouse Ig genes and simultaneously introducing human Ig transgenes at a different and random location. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency.

Leads 52

Leads Pharmaceutical Engineering Marketing 52

Clarivate

MARCH 8, 2022

Dr. Wen-Chien Ko is an infectious disease specialist and Deputy Superintendent of the NCKU Hospital. So far, he has published around 20 papers and been cited internationally over 5,000 times. In January 2021, he planned and guided the erection of the prefab COVID-19 Screening Station with Dr.

Engineering 98

Engineering Government Competition Networking 98

Spotio

JUNE 19, 2022

KO Advantage Group Ltd. Daily: Key Target Conversations and Sales. Weekly: Key Target Conversations, Meetings, Opportunities and Sales. Monthly: Pipeline, Continuations, Sales and % of Goal. Kim Orlesky. Number of calls made (because we can’t get meetings without making phone calls to enough new prospects and clients).

Sales 98

Sales Prospecting Leads Training 98

Celeritas

NOVEMBER 21, 2022

15] Heo DN, Ko WK, Bae MS, et al. 17] Heo DN, Ko WK, Bae MS, et al. . “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction” Proceedings of the National Academy of Sciences. 102 (33): 11600–11605. [14] 14] Pan L, Pei X, He R, Wan Q, Wang J. 18] [link]. [19]

Engineering 52

Engineering Transportation Side effects Networking 52